Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

List of monoclonal antibodies

Introduction

This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see “Nomenclature of monoclonal antibodies“).

Name Target Source
Abagovomab go(v) o
Abciximab ci(r) xi
Adalimumab li(m) u
Adecatumumab tu(m) u
Afelimomab li(m) o
Alemtuzumab tu(m) zu
Altumomab tu(m) o
Ananeuzumab neu(r) zu
Anatumomab mafenatox tu(m) o
Anergrozumab ? zu
Anetumumab tu(m) u
Anrulizumab li(m) zu
Apolizumab li(m) zu
Arcitumomab tu(m) o
Aselizumab li(m) zu
Atlizumab li(m) zu
Atorolimumab li(m) u
Azulizumab li(m) zu
Balizumab li(m) zu
Bapineuzumab neu(r) zu
Basiliximab li(m) xi
Bavituximab tu(m) xi
Bectumomab tu(m) o
Belimumab li(m) u
Belizumab li(m) zu
Bertilimumab li(m) u
Besilesomab le(s) o
Betumumab tu(m) u
Bevacizumab ci(r) zu
Biciromab brallobarbital ci(r) o
Bivatuzumab mertansine tu(m) zu
Campath – Redirects to alemtuzumab tu(m) zu
Canakinumab ki(n) u
Cantuzumab mertansine tu(m) zu
Capromab pr(o) o
Catumaxomab tu(m) axo
Cedelizumab li(m) zu
Certolizumab pegol li(m) zu
Cetforlimumab li(m) u
Cetinlimumab li(m) u
Cetlalimumab li(m) u
Cetolimumab li(m) u
Cetuximab tu(m) xi
Cidfusituzumab tu(m) zu
Cidtuzumab tu(m) zu
Citilimumab li(m) u
Clenoliximab li(m) xi
Cynosumab o(s) u
Cynotumumab – Redirects to cynosumab o(s) u
Dacetuzumab tu(m) zu
Dacliximab – Redirects to daclizumab li(m) zu
Daclizumab li(m) zu
Denosumab o(s) u
Denotumumab – Redirects to denosumab o(s) u
Destilimumab li(m) u
Detumomab tu(m) o
Doraglizumab li(m) zu
Dorlimomab aritox li(m) o
Dorlixizumab li(m) xizu
Dorlizumab li(m) zu
Drinalizumab li(m) zu
Duntumumab tu(m) u
Durimulumab mu(l) u
Durlizumab li(m) zu
Durmulumab mu(l) u
Ecromeximab me(l) xi
Eculizumab li(m) zu
Edobacomab ba(c) o
Edrecolomab co(l) o
Efalizumab li(m) zu
Efungumab fu(ng) u
Elsilimomab li(m) o
Enlimomab pegol li(m) o
Enlimomab li(m) o
Epitumomab cituxetan tu(m) o
Epitumomab tu(m) o
Epkizumab ki(n) zu
Epratuzumab tu(m) zu
Erlizumab li(m) zu
Ertumaxomab tu(m) axo
Etaracizumab ci(r) zu
Etaratuzumab tu(m) zu
Exbivirumab vi(r) u
Extumumab tu(m) u
Efalizumab li(m) zu
Fanolesomab le(s) o
Faralimomab li(m) o
Felvizumab vi(r) zu
Fontolizumab li(m) zu
Futumumab tu(m) u
Galiximab li(m) xi
Gantenerumab ? u
Gavilimomab li(m) o
Gemtuzumab ozogamicin tu(m) zu
Genosumab o(s) u
Golimumab li(m) u
Gomiliximab li(m) xi
Hylizumab li(m) zu
Ibalizumab li(m) zu
Ibritumomab tiuxetan tu(m) o
Igovomab go(v) o
Imciromab ci(r) o
Infliximab li(m) xi
Inolimomab li(m) o
Inotuzumab ozogamicin tu(m) zu
Intumumab tu(m) u
Ipilimumab li(m) u
Iratumumab tu(m) u
Keliximab li(m) xi
Labetuzumab tu(m) zu
Lemalesomab le(s) o
Lebrilizumab li(m) zu
Lerdelimumab li(m) u
Lexatumumab tu(m) u
Lexitumumab tu(m) u
Libivirumab vi(r) u
Lintuzumab tu(m) zu
Lucalizumab li(m) zu
Lucatumumab tu(m) u
Lumiliximab li(m) xi
Mapatumumab tu(m) u
Maslimomab li(m) o
Matenazumab ? zu
Matuzumab tu(m) zu
Mepolizumab li(m) zu
Metelimumab li(m) u
Minretumomab tu(m) o
Mitumomab tu(m) o
Morolimumab li(m) u
Motavizumab vi(r) zu
Muromonab-CD3 monoclonal antibody ? o
Nacolomab tafenatox co(l) o
Naptumomab estafenatox tu(m) o
Natalizumab li(m) zu
Nebacumab ba(c) u
Nerelimomab li(m) o
Nimotuzumab tu(m) zu
Nofetumomab merpentan tu(m) o
Nolovizumab vi(r) zu
Numavizumab vi(r) zu
Ocrelizumab li(m) zu
Odulimomab li(m) o
Ofatumumab tu(m) u
Omalizumab li(m) zu
Oregovomab go(v) o
Oteliximab li(m) xi
Otelixizumab li(m) xizu
Pagibaximab ba(c) xi
Palivizumab vi(r) zu
Panitumumab tu(m) u
Pascolizumab li(m) zu
Pecfusituzumab tu(m) zu
Pectuzumab tu(m) zu
Pemtumomab tu(m) o
Pertuzumab tu(m) zu
Pexelizumab li(m) zu
Pintumomab tu(m) o
Priliximab li(m) xi
Pritumumab tu(m) u
Quartuzumab tu(m) zu
Quetumumab tu(m) u
Ralivizumab vi(r) zu
Ranibizumab ? zu
Raxibacumab ba(c) u
Regavirumab vi(r) u
Resatumumab tu(m) u
Restumumab tu(m) u
Reslivizumab vi(r) zu
Reslizumab li(m) zu
Resyvizumab vi(r) zu
Rilotumumab tu(m) u
Rituximab tu(m) xi
Rosutumumab tu(m) u
Rovelizumab li(m) zu
Ruplizumab li(m) zu
Satumomab tu(m) o
Sevirumab vi(r) u
Sibrotuzumab tu(m) zu
Siplizumab li(m) zu
Sontuzumab tu(m) zu
Stamulumab mu(l) u
Sulesomab le(s) o
Synosumab o(s) u
Tacatuzumab tetraxetan tu(m) zu
Tadocizumab ci(r) zu
Talineuzumab neu(r) zu
Talizumab li(m) zu
Taneuzumab neu(r) zu
Tanirazumab ? zu
Taplitumomab paptox tu(m) o
Tefibazumab ba(c) zu
Teglizumab li(m) zu
Telimomab aritox li(m) o
Teneliximab li(m) xi
Teplizumab li(m) zu
Ticilimumab – Redirects to tremelimumab li(m) u
Tiratumumab tu(m) u
Tocilizumab li(m) zu
Tolizumab li(m) zu
Toralizumab li(m) zu
Tositumomab tu(m) o
Tralizumab li(m) zu
Trastuzumab tu(m) zu
Treglizumab li(m) zu
Trelizumab li(m) zu
Tremelimumab li(m) u
Trilizumab li(m) zu
Tritumumab tu(m) u
Trixatumumab tu(m) u
Tucotuzumab celmoleukin tu(m) zu
Tucusituzumab tu(m) zu
Tuvirumab vi(r) u
Ubrelizumab li(m) zu
Umavizumab vi(r) zu
Urtoxazumab tox(a) zu
Valtumumab tu(m) u
Vapaliximab li(m) xi
Vepalimomab li(m) o
Vexatumumab tu(m) u
Visilizumab li(m) zu
Volociximab ci(r) xi
Votumumab tu(m) u
Xalizumab li(m) zu
Zalutumumab tu(m) u
Zanolimumab li(m) u
Ziralimumab li(m) u
Zolimomab aritox li(m) o
Zulizumab li(m) zu